ALK on my mind: alectinib takes an early lead in managing intracranial disease in non-small cell lung cancer with ALK rearrangements

Tran, P.; Klempner, Samuel J.

doi:10.21037/atm.2017.03.47

Cited by 3 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peters et al determined that alectinib, in particular, appears to have good CNS effect with 17/21 patients having a measurable response and 8/21 having a complete response (Peters et al, 2017). Alectinib will likely take the lead in ALK + NSCLC metastasis therapy and, due to the CNS efficacy, this agent often allows patients to defer surgical resection of their CNS metastases (Gadgeel et al, 2016; Tran and Klempner, 2017). The results of other notable studies on these agents have been organized into a table (Table 1) (Ceresoli, 2004; Iuchi et al, 2013; Welsh et al, 2013; Wu et al, 2013; Costa et al, 2015; Solomon et al, 2016).…”

Section: Specific Considerations For Therapies By Tumor Typementioning

confidence: 99%

Systemic therapy for brain metastases

Rick

Shahin

Chandra

et al. 2019

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Metastases from cells outside of the central nervous system are the most common cancer found in the brain and are commonly associated with poor prognosis. Although cancer treatment is improving overall, central nervous system metastases are becoming more prevalent and require finesse to properly treat. Physicians must consider the biology of the primary tumor and the complex neurological environment that the metastasis resides in. This can be further complicated by the fact that the practice of cancer management is constantly evolving and therapy that works outside of the blood-brain barrier may not be effective inside of it. Therefore, this review seeks to update the reader on recent advancements made on the three most common sources of brain metastases: lung cancer, breast cancer, and melanoma. Each of these malignancies has been the subject of intriguing and novel avenues of therapy which are reviewed here.

show abstract

Section: Specific Considerations For Therapies By Tumor Typementioning

confidence: 99%

Systemic therapy for brain metastases

Rick

Shahin

Chandra

et al. 2019

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

show abstract

Drug Delivery to Primary and Metastatic Brain Tumors: Challenges and Opportunities

Talele

Mohammad

Schulz

et al. 2022

Drug Delivery to the Brain

View full text Add to dashboard Cite

<p>Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)–Positive Non–Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors</p>

Singh

Chen

2020

CMAR

View full text Add to dashboard Cite

The treatment of advanced non-small-cell lung cancer (NSCLC) has undergone a paradigm shift in the last decade. Molecular characterization of the disease has led to the rapid development of personalized medicine and swift delivery of targeted therapies to patients. The discovery of the anaplastic lymphoma kinase (ALK) gene in patients with NSCLC has resulted in rapid bench-bedside transition of several active drugs, with several others currently in clinical trials. After the first-generation ALK inhibitor crizotinib, nextgeneration ALK inhibitors have entered clinical applications for ALK-rearranged NSCLC. Ceritinib, alectinib, and brigatinib have all received approval for ALK-positive patients who have failed prior crizotinib, as well as first-line therapy in treatment-naïve patients based on favorable efficacy. Most recently, lorlatinib, a potent, newer-generation ALK inhibitor, has been approved as second-or third-line treatment. These advances have led to better patient outcomes, but concurrently have led to several crucial unanswered questions about optimal care for ALK-positive NSCLC patients. The ultimate acquisition of resistance to ALKinhibitor therapy poses a challenge to ongoing research efforts, in addition to the routine management of these patients in the clinic. This review provides a summary of the clinical development of crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib and highlights current management paradigms, current and evolving clinical information, emerging clinical decision-making and sequencing of therapy in advanced, metastatic, or recurrent ALK-positive NSCLC.

show abstract

ALK on my mind: alectinib takes an early lead in managing intracranial disease in non-small cell lung cancer with ALK rearrangements

Cited by 3 publications

References 20 publications

Systemic therapy for brain metastases

Systemic therapy for brain metastases

Drug Delivery to Primary and Metastatic Brain Tumors: Challenges and Opportunities

<p>Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)–Positive Non–Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors</p>

Contact Info

Product

Resources

About